Yan Z, Cao J, Cheng H, et al. - In this single-centre, single-arm, phase 2 trial run in China, researchers tested a combination of humanised anti-CD19 and anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells with respect to activity and safety in patients with relapsed or refractory multiple myeloma. Prior to the infusion of humanised anti-CD19 CAR T cells (1 × 10⁶ cells per kg) and murine anti-BCMA CAR T cells (1 × 10⁶ cells per kg), lymphocytes were depleted using fludarabine (three daily doses of 30mg/m²) and cyclophosphamide (one daily dose of 750 mg/m²). A median follow-up of 179 days (IQR 72–295) revealed the achievement of overall response in 20 (95%) of 21 patients. Findings confirmed the feasibility of the combined infusion of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma. The combination also displayed preliminary activity in these patients, which needs to be further tested in randomised trials. For relapsed or refractory multiple myeloma, the possible promising therapeutic efficacy of this dual CAR-T cell combinations was suggested.